BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29021377)

  • 1. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.
    Ciombor KK; Bekaii-Saab T
    Oncologist; 2018 Jan; 23(1):25-34. PubMed ID: 29021377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted drugs for metastatic colorectal cancer.
    Cheng YD; Yang H; Chen GQ; Zhang ZC
    Drug Des Devel Ther; 2013; 7():1315-22. PubMed ID: 24204124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment sequencing in metastatic colorectal cancer.
    Modest DP; Pant S; Sartore-Bianchi A
    Eur J Cancer; 2019 Mar; 109():70-83. PubMed ID: 30690295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
    Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
    Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
    Lee JJ; Sun W
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ; García-Paredes B; Aguado C; Sastre J; Díaz-Rubio E
    World J Gastroenterol; 2014 Apr; 20(15):4208-19. PubMed ID: 24764659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
    Eng C
    Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
    Udar N; Lofton-Day C; Dong J; Vavrek D; Jung AS; Meier K; Iyer A; Slaughter R; Gutekunst K; Bach BA; Peeters M; Douillard JY
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):2001-2010. PubMed ID: 30019318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
    Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS
    J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
    Bekaii-Saab T; Wu C
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):9-34. PubMed ID: 24534706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current controversies in the management of metastatic colorectal cancer.
    Vera R; Alonso V; Gállego J; González E; Guillén-Ponce C; Pericay C; Rivera F; Safont MJ; Valladares-Ayerbes M
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):659-77. PubMed ID: 26113053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.